Peripheral Arterial Disease Clinical Trial
— TOBA IIIOfficial title:
Tack Optimized Drug Coated Balloon Angioplasty in the Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System™
NCT number | NCT02802306 |
Other study ID # | CA 0135 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2016 |
Est. completion date | May 2020 |
Verified date | April 2021 |
Source | Philips Clinical & Medical Affairs Global |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an Outside the United States, post-CE Mark, multi-center, single-arm, non-blinded study designed to investigate the safety and efficacy of the Tack Endovascular System. This study will evaluate subjects with PAD who receive PTA (with a drug-coated balloon (DCB)) in the SFA and in popliteal arteries, ranging in diameter from 2.5mm to 6.0mm and lesion lengths of ≥20mm and ≤150mm, and have a resulting dissection(s) type(s) A through F. TOBA III will also evaluate the safety and efficacy of the device when used to treat a sub-group presenting with longer lesions of >150mm and ≤250mm.
Status | Completed |
Enrollment | 201 |
Est. completion date | May 2020 |
Est. primary completion date | May 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject must meet all of the following inclusion criteria to be eligible for enrollment: 1. Male or non-pregnant Female = 18 years of age at the time of consent 2. Female subjects of childbearing potential must have a negative pregnancy test prior to treatment and must use some form of contraception through the duration of the study 3. Target limb requires no additional treatment aside from the target lesion and the iliac artery(ies) during the index procedure 4. Subject or has been informed of and understands the nature of the study and provides signed informed consent to participate in the study. If the subject possesses the ability to understand and provide informed consent but due to physical inability, the subject cannot sign the ICF, an impartial witness may sign on behalf of the subject 5. Willing to comply with all required follow-up visits 6. Rutherford Classification 2, 3 or 4 7. Estimated life expectancy >1 year 8. Eligible for standard surgical repair, if necessary 9. Subject is ambulatory (assistive devices such as a cane or walker is acceptable Exclusion Criteria: - Subject must NOT meet any of the following exclusion criteria to be eligible for enrollment: 1. Rutherford Classification 0, 1, 5 or 6 2. Is pregnant or refuses to use contraception through the duration of the study 3. Previous infrainguinal bypass graft in the target limb 4. Planned amputation on the target limb 5. Systemic infection or infection within the target limb and/or immunocompromised 6. Endovascular or surgical procedure (not including diagnostic procedures) on the target limb within 30 days prior to or within 30 days after the index procedure 7. Endovascular or surgical procedure (not including diagnostic procedures) on the non-target limb within 14 days prior to the index procedure or planned procedure within 30 days after the index procedure 8. Prior coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) procedure within 30 days prior to the index procedure or planned CABG/PCI within 30 days after the index procedure 9. Any other previous or planned surgical or endovascular procedure (not including diagnostic procedures) within 14 days prior to or 30 days post index procedure 10. Planned atherectomy, cryoplasty, stenting or any other treatment (with the exception of a crossing device) of the target lesion other than PTA during the index procedure 11. Known coagulopathy, hypercoagulable state, bleeding diathesis, other blood disorder, or a platelet count less than 80,000/microliter or greater than 500,000/microliter 12. Known hypersensitivity or allergy to antiplatelet or anticoagulant therapy 13. Myocardial infarction within 30 days prior to enrollment 14. History of stroke within 90 days prior to enrollment 15. Serum creatinine of >2.5 mg/dL 16. Requires treatment of tibial or outflow vessels at the index procedure, which include the P2 and P3 segments of the popliteal artery and the tibioperoneal vessels 17. Known hypersensitivity or contraindication to nickel-titanium alloy (Nitinol) 18. Participating in another ongoing investigational clinical trial that has not completed its primary endpoint 19. Has other comorbidities that, in the opinion of the investigator, would preclude them from receiving this treatment and/or participating in study-required follow-up assessments 20. Known hypersensitivity or allergy to contrast agents that cannot be medically managed 21. Thrombolysis of the target vessel within 72 hours prior to the index procedure, where complete resolution of the thrombus was not achieved |
Country | Name | City | State |
---|---|---|---|
Austria | University Hospital AKH Vienna | Wien | |
Belgium | Imelda Hosptial | Bonheiden | |
Belgium | A.Z. St. Blasius Hospital | Dendermonde | |
Germany | Karolinen-Hospital Klinik für Angiologie Arnsberg Clinic | Arnsberg | |
Germany | Universitats-Herzzentrum Freiburg-Bad Krozingen Klinik fur Kardiologie und Angiologie lI | Bad Krozingen | |
Germany | Franziskus-Hospital Berlin | Berlin | |
Germany | Medizinische Klinik II Fürst Stirum Klinik Bruchsal | Bruchsal | |
Germany | Universitätsklinikum Carl Gustav Carus | Dresden | |
Germany | Asklepios Klinik St. Georg Herz-, Gefäß- und Therapiezentrum, Abt. Klinische und Interventionelle Angiologie | Hamburg | |
Germany | Center for Cardiology & Vascular Intervention | Hamburg | |
Germany | Westküstenklinikum Heide | Heide | |
Germany | Herz und Gefäßzentrum im Klinikverbund Oberallgäu-Kempten | Immenstadt | |
Germany | Klinikum Karlsbad Langensteinbach | Karlsbad | |
Germany | Universitätsklinik Leipzig | Leipzig | |
Germany | Universitätsmedizin Mainz II Medizinische Klinik und Poliklinik, Angiologie | Mainz | |
Switzerland | Cantonal Hospital Lucerne Division of Angiology | Lucerne | |
Switzerland | Ospedale Regionale di Lugano - Civico e Italiana Civico | Lugano |
Lead Sponsor | Collaborator |
---|---|
Philips Clinical & Medical Affairs Global |
Austria, Belgium, Germany, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety - Freedom from the occurrence of any new-onset major adverse event(s) | Freedom from the occurrence of any new-onset major adverse event(s) (MAEs) defined as index limb amputation (above the ankle), CEC adjudicated clinically-driven target lesion revascularization (CD-TLR), or all-cause death at 30 days. | 30 days | |
Primary | Efficacy - Primary Patency | Primary patency defined as freedom from CEC adjudicated clinically driven target lesion revascularization (CD-TLR) and freedom from core lab adjudicated duplex ultrasound derived binary restenosis at 12 months (defined as PSVR >2.5:1). | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Completed |
NCT02022423 -
Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease
|
N/A |